The labeling for Onglyza (saxagliptin; Bristol-Myers Squibb) has been updated to include data from two clinical trials: a study of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD) and a second comparator study of Onglyza + metformin versus glipizide + metformin.
Your search for esrd returned 114 results
BELLUS Health and Celtic Therapeutics announced that a global confirmatory Phase 3 study was initiated for their orphan status drug, Kiacta (eprodisate), for the treatment of Amyloid A (AA) amyloidosis.
Keryx announced results from its Phase 3 trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Keryx Biopharmaceuticals announced results from the Phase 2 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis.